Embla Medical: All eyes on US in Q3 - ABG

Solid Q3e with 7% organic growth and 22% EBITDA growth
US market could be sluggish again, but focus is on 2025
We reiterate our fair value range of DKK 27-40


Q3 on 22 Oct @ 07:00 CET, CC @ 09:00 CET

We look for Embla to report a Q3 with USD 210m in sales (-1% vs company-collected consensus) on 7% organic growth (cons. 7%). We assume a 64.1% gross margin (+60bp vs cons.), filtering through to EBITDA pre-items of USD 44.4m (+1% vs cons.). We are 8% ahead on EPS at USD 19.7 cents (18.2c cons.).

Länk till analysen i sin helhet: https://cr.abgsc.com/foretag/embla_medical/Equity-research/2024/10/embla-medical---all-eyes-on-us-in-q3/